Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase NA 7Phase EARLY_PHASE1 3Phase 1/2 2Phase 1 2Phase 3 1Phase 2/3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 276Brain Neoplasms 169Glioma 139Central Nervous System Neoplasms 85Gliosarcoma 79Astrocytoma 74Neuroblastoma 64Oligodendroglioma 42Neoplasms 40Breast Neoplasms 38Recurrence 37Carcinoma, Non-Small-Cell Lung 31Medulloblastoma 27Melanoma 26Ovarian Neoplasms 24Lymphoma 21Diffuse Intrinsic Pontine Glioma 21Sarcoma 19Neoplasm Metastasis 19Lung Neoplasms 18Colorectal Neoplasms 17Rhabdomyosarcoma 16Osteosarcoma 16Meningeal Carcinomatosis 15Ependymoma 15Pancreatic Neoplasms 14Meningioma 14Sarcoma, Ewing 13Stomach Neoplasms 12Esophageal Neoplasms 12

Interventions

Doxycycline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neurofibromatosis 2 × CNS × Clear all
NCT07131722 2026-01-23

Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II

PRG Science & Technology Co., Ltd.

Phase 1/2 Not yet recruiting
25 enrolled
CNS

Neurofibromatosis 2

NCT05521048 2025-12-08

Doxycycline in Cutaneous Schwannoma (NF2)

Massachusetts Eye and Ear Infirmary

Phase 1/2 Active not recruiting
19 enrolled
CNS

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡